Melanotan (One) “afamelanotide” NBC News Report, November 1991

Melanotan (one) “afamelanotide” NBC News report, November 1991 – Melanotan (one) “afamelanotide” discovery by researchers at the University of Arizona in Tucson as explained by NBC News’ Robert Bazell (with Tom Brokaw introduction) in a November 1991 News report. Melanotan (one) is now being developed in Australia as a photoprotective medicine to treat people who’s skin is negatively affected (more than normal) by exposure to UV light. Clinuvel (originally named “Epitan”) is the company that has been working to develop it since 1999. They are currently conducting clinical trials (under the drug name “afamelanotide”). The expected release of Melanotan one on the market as a treatment option for Erythropoietic Protoporphyria (EPP) sufferers is likely to be either 2009 or 2010. Journal of the American Medical Association article that this report was based upon: jama.ama-assn.org www.clinuvel.com en.wikipedia.org melanotan.org afamelanotide

Neuralstem Is Speculative, But Its Work In Stem Cell Therapy Can't Be Ignored

Filed under: drug treatment news articles

I have no business relationship with any company whose stock is mentioned in this article. (More…) Introduction. I think that the potential of stem cell therapy has captured the imagination of … Using this approach, it has developed a new small …
Read more on Seeking Alpha

Vivus Or Arena: Who Has The Edge?

Filed under: drug treatment news articles

… it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. (More…) Two of the three major players in the treatment of obesity, VIVUS Inc. (VVUS) and Arena Pharmaceuticals Inc …
Read more on Seeking Alpha